OncLive TV

Effects of Testosterone-Lowering Drugs in Patients With Prostate Cancer

September 13th 2016

Heather S. Jim, PhD, associate member in the Health Outcomes and Behavioral Department, Moffitt Cancer Center, discusses the effects of testosterone-lowering drugs used as a treatment for patients with prostate cancer.

Dr. Kim on Combination Therapies in Lung Cancer

September 13th 2016

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses combination therapies in the treatment of patients with lung cancer.

Dr. White on Omitting Radiation in Breast Cancer

September 13th 2016

Julia White, MD, professor of Radiation Oncology, Ohio State University Comprehensive Cancer Center, discusses the omission of radiation therapy for patients with breast cancer.

Dr. Schoenfeld on Synergy Between Radiation and Immunotherapy in SCCHN

September 13th 2016

Dr. Sundar Jagannath on Three-Drug Regimen for Newly Diagnosed Multiple Myeloma

September 12th 2016

Dr. Markman on Timing of BSO in Patients With Ovarian Cancer

September 12th 2016

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses when patients with ovarian cancer should undergo a bilateral salpingo-oophorectomy (BSO).

Dr. Kumar Discusses the Role of Stem Cell Transplant in Multiple Myeloma

September 10th 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the role of stem cell transplant in treating patients with multiple myeloma.

Dr. Anderson on Superoxide Dismutase Mimetic GC4419 in Treating Patients With Oropharyngeal Carcinoma

September 10th 2016

Carryn Anderson, MD, assistant professor of Radiation Oncology, University of Iowa, discusses a phase Ib/IIa study of superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavitiy or oropharyngeal carcinoma.

Dr. D'Orazio on UV Signature Mutations in Melanoma

September 9th 2016

John A. D'Orazio, MD, PhD, associate professor, Department of Pediatrics, College of Medicine, University of Kentucky Markey Cancer Center, discusses ongoing research exploring ultraviolet radiation signature mutations in patients with melanoma.

Dr. DeMichele on Importance of Neoadjuvant Care in HER2+ Breast Cancer

September 9th 2016

Angela M. DeMichele, MD, professor of Medicine and Epidemiology, University of Pennsylvania, discusses the importance of neoadjuvant treatment for patients with HER2-positive breast cancer.

Dr. Postow on the Current Treatment Landscape in Melanoma

September 8th 2016

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the current treatment landscape in melanoma.

Dr. Dreicer on Resistance to Antiandrogen Therapy in Prostate Cancer

September 8th 2016

Robert Dreicer, MD, Division of Hematology/Oncology, Department of Medicine, University of Virginia Health System, discusses resistance to antiandrogen therapy in prostate cancer.

Dr. Mamounas on Adverse Events With Mastectomy in Breast Cancer

September 8th 2016

Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health, discusses the common adverse events associated with mastectomy and breast conserving surgery for patients with breast cancer, as well as how oncologists can best manage these toxicities.

Dr. Stevenson on Potential of Immunotherapy in Squamous NSCLC

September 8th 2016

James Stevenson, MD, medical oncologist at Cleveland Clinic, discusses the potential of immunotherapy agents as treatment for patients with squamous non–small cell lung cancer (NSCLC).

Dr. Decker on Stereotactic Body Radiation Therapy in Lung Cancer

September 8th 2016

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses stereotactic body radiation therapy (SBRT) as a treatment for patients with lung cancer.

Dr. Strosberg on the Results of the NETTER-1 Trial

September 8th 2016

Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the results of the NETTER-1 trial.

Dr. Donnellan on TFR in Patients With CML Treated With Nilotinib

September 7th 2016

William B. Donnellan, MD, investigator, Hematologic Malignancies, principal investigator, Sarah Cannon Research Institute, discusses preliminary results of the ENESTop study, which looked at treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase who were treated with second-line nilotinib (Tasigna).

Dr. Esteva on Clinical Trial Design of Trastuzumab Biosimilar in HER2+ Breast Cancer

September 7th 2016

Francisco J. Esteva, MD, PhD, medical oncologist, New York Langone Medical Center, discusses the importance of having a clinical trial of the trastuzumab (Herceptin) biosimilar MYL-1401O for patients with HER2-positive breast cancer.

Dr. McDermott on Major Findings of Efficacy and Safety of Nivolumab in RCC

September 7th 2016

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the findings of the phase III CheckMate-025 trial of nivolumab (Opdivo) versus everolimus (Afinitor) in renal cell carcinoma (RCC).

Dr. Randolph on Evolving Role of Surgery for Patients With Thyroid Cancer

September 6th 2016

Gregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, discusses how the role of surgery has evolved for patients with thyroid cancer.